Comparison of predictive and prognostic impact of molecular subtypes and central grade regarding taxane-based therapy in intermediate-risk breast cancer: Results from the EC-Doc trial.
U. Nitz
Honoraria - Amgen; Sanofi
Other Remuneration - Amgen; Sanofi
O. Gluz
Honoraria - Sanofi
C. Liedtke
Honoraria - Sanofi
Other Remuneration - Sanofi
J. B. Huober
Consultant or Advisory Role - Amgen; Sanofi
Honoraria - Amgen; Sanofi
A. Hartmann
No relevant relationships to disclose
R. E. Kates
No relevant relationships to disclose
H. H. Kreipe
No relevant relationships to disclose
E. Pelz
No relevant relationships to disclose
W. Kuhn
No relevant relationships to disclose
N. Harbeck
Honoraria - Amgen; Sanofi
Other Remuneration - Amgen; Sanofi